$34.330
+0.151 (+0.44%)Zum Schluss
KN-News
KN-Events
Knowles Partners with Elucent Medical to Produce Smart Surgical Guidance Device
Knowles announced an agreement to produce Elucent Medical's smart surgical guidance device for use with its EnVisio In-Body Spatial IntelligenceTM System. Leveraging Knowles' micro molding capabilities and using a design-for-manufacturability, or DFM, optimization approach, Knowles worked with Elucent to iterate designs, identify tolerance and material improvement opportunities, and provide guidance throughout product design, development, and launch of their surgical guidance device.
Knowles Reports Q2 Revenue of $167M
Reports Q2 revenue $167M, consensus $156.97M. "We delivered second quarter revenues exceeding the high end of our guided range. Non-GAAP diluted EPS was above the high end of our guided range and cash from operations was within the guided range," commented Jeffrey Niew, President and CEO of Knowles.
Sees Q3 Revenue of $167M-$177M
Sees Q3 revenue $167M-$177M, consensus $163.45M.
Company Reports Q1 Revenue of $153.1M, Exceeding Expectations
Reports Q1 revenue $153.1M, consensus $147.4M. "We started 2026 delivering strong first quarter revenues and non-GAAP diluted EPS which was at or above the high-end of our guided ranges," commented Jeffrey Niew, CEO. "We are executing on our strategy, continuing to leverage our unique technologies, creating custom products through our customer application intimacy, and then scaling into production with our world-class operational capabilities. Our end markets of Medtech, Defense, Industrial and Electrification are also benefiting from strong secular growth trends. With this powerful combination, our revenue grew 16% on a year-over-year basis in the first quarter, exceeding our five-year annual organic growth target. Our revenue growth was complemented by substantial gross margin expansion resulting in significant year-over-year EPS growth. We have numerous new design wins ramping across multiple end markets and a very healthy backlog of existing orders, positioning us well to continue to deliver year over year organic revenue and adjusted EBITDA growth in 2026 above the high-end of our annual growth targets as presented in our May 2025 investor day."
Sees Q1 Revenue of $143M-$153M
Sees Q1 revenue $143M-$153M, consensus $143.1M
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.